Vihko R, Jänne O, Kauppila A
Ann Clin Res. 1980 Oct;12(5):208-15.
Oestrogen and progestin receptors are present in the cytosol and nuclear compartments of normal human endometrium, partly associated with their endogenous ligand hormones. Receptor concentrations fluctuate in relation to the menstrual cycle. Hyperplastic endometrium tends to contain high concentrations of cytosol progestin receptor, whereas the levels of cytosol and nuclear progestin receptors in endometrial adenocarcinoma are lower than in non-neoplastic endometrium. The receptor levels seem to decline with decreasing differentiation of the tumour. Progestin treatment extending over several weeks decreases cellular oestrogen and progestin receptor content in both hyperplastic and malignant endometria. Information based on small patient series suggests that patients suffering from advanced or recurrent endometrial carcinoma and having significant concentrations of both receptors in the tumour tend to have a more indolent clinical course than patients with absent or low tumour receptors. Patients whose lesions are progestin receptor-rich more frequently respond to progestin administration than those with receptor-poor tumours. In contrast, patients with advanced or recurrent disease after progestin treatment and with low tumour oestrogen and progestin receptor concentrations respond more often to combination cytotoxic chemotherapy than patients with higher tumour receptor levels. More data are needed about the clinical correlates of receptor determinations in human endometrial carcinoma to confirm these encouraging preliminary results, before the clinical significance of the determinations can be settled. since there are marked differences in the receptor concentrations reported by various investigators, possibly for methodological reasons, comparison of receptor data and treatment results from different groups is sometimes very difficult.
雌激素和孕激素受体存在于正常人类子宫内膜的细胞质和细胞核区室中，部分与它们的内源性配体激素相关。受体浓度随月经周期而波动。增生性子宫内膜往往含有高浓度的细胞质孕激素受体，而子宫内膜腺癌中细胞质和细胞核孕激素受体的水平低于非肿瘤性子宫内膜。受体水平似乎随着肿瘤分化程度的降低而下降。持续数周的孕激素治疗会降低增生性和恶性子宫内膜中细胞的雌激素和孕激素受体含量。基于小样本患者系列的信息表明，患有晚期或复发性子宫内膜癌且肿瘤中两种受体浓度显著的患者，其临床病程往往比肿瘤受体缺失或水平低的患者更为惰性。肿瘤富含孕激素受体的患者比受体缺乏的肿瘤患者对孕激素给药的反应更频繁。相比之下，孕激素治疗后患有晚期或复发性疾病且肿瘤雌激素和孕激素受体浓度低的患者，比肿瘤受体水平较高的患者对联合细胞毒性化疗的反应更频繁。在确定这些检测的临床意义之前，还需要更多关于人类子宫内膜癌受体检测临床相关性的数据来证实这些令人鼓舞的初步结果。由于不同研究者报告的受体浓度存在显著差异，可能是方法学原因，不同组之间受体数据和治疗结果的比较有时非常困难。
